H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 130 KRW 1.92% Market Closed
Market Cap: 192.5B KRW
Have any thoughts about
Hana Pharm Co Ltd?
Write Note

Hana Pharm Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hana Pharm Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
H
Hana Pharm Co Ltd
KRX:293480
Short-Term Debt
â‚©2B
CAGR 3-Years
0%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Short-Term Debt
â‚©131.7B
CAGR 3-Years
27%
CAGR 5-Years
47%
CAGR 10-Years
18%
SK Biopharmaceuticals Co Ltd
KRX:326030
Short-Term Debt
â‚©50B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Short-Term Debt
â‚©372.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
25%
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Short-Term Debt
â‚©22.5B
CAGR 3-Years
115%
CAGR 5-Years
51%
CAGR 10-Years
20%
C
Celltrion Pharm Inc
KOSDAQ:068760
Short-Term Debt
â‚©150.5B
CAGR 3-Years
7%
CAGR 5-Years
8%
CAGR 10-Years
7%
No Stocks Found

Hana Pharm Co Ltd
Glance View

Market Cap
192.5B KRW
Industry
Pharmaceuticals

Hana Pharm Co., Ltd. engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 657 full-time employees. The company went IPO on 2018-10-02. The company’s main products include cardiovascular drugs involves hypertension and hyperlipidemia medicines, as well as blood circulation improvement drugs; analgesics for severe pain and anesthetics for surgery and sedation; as well as gastrointestinal drugs such as peptic ulcer treatment and antispasmodics. The firm also provides antibiotics, dermatology analgesics, antipyretics and anti-inflammatory drugs.

Intrinsic Value
18 041.77 KRW
Undervaluation 38%
Intrinsic Value
Price
H

See Also

What is Hana Pharm Co Ltd's Short-Term Debt?
Short-Term Debt
2B KRW

Based on the financial report for Sep 30, 2024, Hana Pharm Co Ltd's Short-Term Debt amounts to 2B KRW.

What is Hana Pharm Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 5Y
-29%

Over the last year, the Short-Term Debt growth was -71%.

Back to Top